Physician profile
Samuel Ryan Morris
NPI 1043536899
$8,833.27
in general payments reported to CMS, 2019-2025
41 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $772 · 2021: $829 · 2022: $1,128 · 2023: $1,485 · 2024: $1,497 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,240.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,196.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $946.41 | 2021-2025 | |
| Pfizer INC. | $712.78 | 2019-2025 | |
| Novo Nordisk INC | $587.12 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Glaxosmithkline, LLC. | $507.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $387.97 | 2021-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $365.37 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $307.82 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $260.51 | 2019-2023 | Xarelto |
| Abbott Laboratories | $248.43 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $244.03 | 2021-2025 | Rexulti |
| Allergan, INC. | $203.04 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $178.84 | 2019-2025 | Eliquis |
| Idorsia Pharmaceuticals US INC | $159.34 | 2023-2024 | Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.